A mechanistic classification of clinical phenotypes in neuroblastoma

Copy-number analysis and inference of subclonal populations in cancer genomes using Sclust

(2018) Yupeng Cun et al.   Nature Protocols

Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors

(2016) Aatur D. Singhi et al.   CLINICAL CANCER RESEARCH

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma

(2016) Lori S. Hart et al.   CLINICAL CANCER RESEARCH

Derepression ofhTERTgene expression promotes escape from oncogene-induced cellular senescence

(2016) Priyanka L. Patel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Telomerase activation by genomic rearrangements in high-risk neuroblastoma

(2015) Martin Peifer et al.   NATURE

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

(2015) Thomas F Eleveld et al.   NATURE GENETICS

Mutational dynamics between primary and relapse neuroblastomas

(2015) Alexander Schramm et al.   NATURE GENETICS

TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors

(2015) Linda J Valentijn et al.   NATURE GENETICS

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors

(2015) R. L. Flynn et al.   SCIENCE

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma

(2015) N. R. Infarinato et al.   Cancer Discovery

Comparison of RNA-seq and microarray-based models for clinical endpoint prediction

(2015) Wenqian Zhang et al.   GENOME BIOLOGY

Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays

(2014) Martin J. Aryee et al.   BIOINFORMATICS

ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma

(2014) Scott C. Bresler et al.   CANCER CELL

Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

(2014) A. Oberthuer et al.   CLINICAL CANCER RESEARCH

COSMIC: exploring the world's knowledge of somatic mutations in human cancer

(2014) Simon A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Induction of Telomere Dysfunction Mediated by the Telomerase Substrate Precursor 6-Thio-2′-Deoxyguanosine

(2014) Ilgen Mender et al.   Cancer Discovery

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

(2013) Yael P Mossé et al.   LANCET ONCOLOGY

The genetic landscape of high-risk neuroblastoma

(2013) Trevor J Pugh et al.   NATURE GENETICS

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

(2012) Xiao-Yang Liu et al.   ACTA NEUROPATHOLOGICA

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma

(2012) Teeara Berry et al.   CANCER CELL

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

(2012) Marcin Imielinski et al.   CELL

Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma

(2012) Nai-Kong V. Cheung   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes

(2012) Jan J. Molenaar et al.   NATURE

Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice

(2012) L. C. Heukamp et al.   Science Translational Medicine

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma

(2010) J. Carr-Wilkinson et al.   CLINICAL CANCER RESEARCH

Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients

(2010) A Oberthuer et al.   PHARMACOGENOMICS JOURNAL

Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma

(2009) Isabelle Janoueix-Lerosey et al.   JOURNAL OF CLINICAL ONCOLOGY

DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity

(2009) Jeremy D Henson et al.   NATURE BIOTECHNOLOGY

The estimation of average hazard ratios by weighted Cox regression

(2009) Michael Schemper et al.   STATISTICS IN MEDICINE

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

(2008) Susan L. Cohn et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of ALK as a major familial neuroblastoma predisposition gene

(2008) Yaël P. Mossé et al.   NATURE